Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency by Joseph S. Palumbo, Kathryn E. Talmage, Hong Liu,

Slides:



Advertisements
Similar presentations
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Endothelial Cell Hypertrophy Induced by Vascular.
Advertisements

Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent.
Lack of Platelet Endothelial Cell Adhesion Molecule-1 Attenuates Foreign Body Inflammation because of Decreased Angiogenesis  Anna Solowiej, Purba Biswas,
Reduced Tumor Necrosis Factor-α and Transforming Growth Factor-β1 Expression in the Lungs of Inbred Mice that Fail to Develop Fibroproliferative Lesions.
Tumor-Induced Sentinel Lymph Node Lymphangiogenesis and Increased Lymph Flow Precede Melanoma Metastasis  Maria I. Harrell, Brian M. Iritani, Alanna Ruddell 
Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development by Tomihisa Kawasaki, Mieke Dewerchin,
Mesenchymal stem cells attenuate angiotensin II-induced aortic aneurysm growth in apolipoprotein E-deficient mice  Ryotaro Hashizume, MD, Aika Yamawaki-Ogata,
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice by Deanna Grote, Stephen J. Russell, Tatjana I. Cornu,
Platelet-associated PF-4 as a biomarker of early tumor growth
by Koji Yamamoto, Vivian de Waard, Colleen Fearns, and David J
Hematopoietic cells regulate the angiogenic switch during tumorigenesis by Rika Okamoto, Masaya Ueno, Yoshihiro Yamada, Naoko Takahashi, Hideto Sano, Toshio.
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain by Netanel A. Horowitz,
Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization by Emília Ilona Gaál,
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis by Hajime.
by Leila M. Lopes Bezerra, and Scott G. Filler
SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness by Jeffrey.
Volume 87, Issue 4, Pages (November 1996)
A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression by Rosalba Salcedo, Maria Lourdes.
VEGF Gene Delivery to Muscle
Matthias W. Laschke, M. D. , Antje Elitzsch, D. V. M
Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis
by Sara M. Weis, Jeffrey N. Lindquist, Leo A. Barnes, Kimberly M
Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Volume 7, Issue 3, Pages (March 2003)
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Volume 85, Issue 2, Pages (January 2014)
Long-term patency of small-diameter vascular graft made from fibroin, a silk-based biodegradable material  Soichiro Enomoto, MD, PhD, Makoto Sumi, MD,
Volume 26, Issue 1, Pages (January 2018)
Volume 18, Issue 10, Pages (October 2010)
Volume 1, Issue 2, Pages (March 2002)
Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease  Alessandra Bitto, MD, Francesca Polito,
Rejuvenation of Regeneration in the Aging Central Nervous System
Katerina Akassoglou, Wei-Ming Yu, Pinar Akpinar, Sidney Strickland 
Volume 123, Issue 6, Pages (December 2005)
The hypoxic response of tumors is dependent on their microenvironment
Volume 22, Issue 1, Pages (July 2012)
Volume 10, Issue 5, Pages (November 2004)
Deficiency of hyaluronan synthase 1 (Has1) results in chronic joint inflammation and widespread intra-articular fibrosis in a murine model of knee joint.
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice by Rikke Stagaard, Carsten Dan Ley, Kasper Almholt,
Matthias W. Laschke, M. D. , Antje Elitzsch, D. V. M
Randall Adolph, BS, David A. Vorp, PhD, David L. Steed, MD, Marshall W
Silvina Gazzaniga, Alicia Bravo, Silvana R
VAY-736 combines effectively with ibrutinib in vivo.
The Neurofibromatosis Type 1 (Nf1) Tumor Suppressor is a Modifier of Carcinogen- Induced Pigmentation and Papilloma Formation in C57BL/6 Mice  Radhika.
Volume 17, Issue 10, Pages (October 2009)
Judith A. Mack, Edward V. Maytin  Journal of Investigative Dermatology 
Role of VEGF-A in Vascularization of Pancreatic Islets
The Nf1 Tumor Suppressor Regulates Mouse Skin Wound Healing, Fibroblast Proliferation, and Collagen Deposited by Fibroblasts  Radhika P. Atit, Maria J.
Volume 17, Issue 2, Pages (February 2009)
Phosphorylation of TRIO Y2681 in human colorectal cancer (CRC) is correlated with poorer prognosis. Phosphorylation of TRIO Y2681 in human colorectal cancer.
Paclitaxel Encapsulated in Cationic Liposomes Diminishes Tumor Angiogenesis and Melanoma Growth in a “Humanized” SCID Mouse Model  Rainer Kunstfeld, Georg.
Ultraviolet B-Induced Skin Angiogenesis Is Associated with a Switch in the Balance of Vascular Endothelial Growth Factor and Thrombospondin-1 Expression 
Normal Wound Healing in Mice Deficient for Fibulin-5, an Elastin Binding Protein Essential for Dermal Elastic Fiber Assembly  Qian Zheng, Jiwon Choi,
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 22, Issue 1, Pages (July 2012)
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Instigating, noninstigating, and responding human tumor specimens.
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Richard L. Binns, MD  Journal of Vascular Surgery 
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells by Sherry Thornton, Harini Raghu,
Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells by Barbara Costa, Tanja.
Vessel density is decreased in tumors grown in Fbln5−/− mice.
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Figure 1 A B GCL NBL ED18.5 PND3 PND6 GCL
Volume 23, Issue 3, Pages (March 2015)
The Angiogenesis Inhibitor Vasostatin does not Impair Wound Healing at Tumor- Inhibiting Doses  Bernhard Lange-Asschenfeldt, Paula Velasco, Michael Streit,
Volume 16, Issue 10, Pages (October 2008)
Presentation transcript:

Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency by Joseph S. Palumbo, Kathryn E. Talmage, Hong Liu, Christine M. La Jeunesse, David P. Witte, and Jay L. Degen Blood Volume 102(8):2819-2827 October 15, 2003 ©2003 by American Society of Hematology

Plasminogen is a determinant of LLC tumor growth through a mechanism linked to anatomic location. Plasminogen is a determinant of LLC tumor growth through a mechanism linked to anatomic location. (A) Tumor mass after LLCGFP transplantation into the dorsal subcutis of control (•, n = 4) and plasminogen-deficient (○, n = 5) mice was estimated by serial calipation. Tumor sizes were not significantly different between the cohorts at any time point. Direct tumor weight measurements made at the time of animal killing were also not significantly different (data not shown). Tumor size after LLCGFP transplantation into the footpad was estimated by serial calipation of tumor width (B) and direct tumor weight at day 14 (C) in the footpad of control (•, n = 6) and plasminogen-deficient (○, n = 7) mice. Footpad tumors in plasminogen-deficient mice were significantly smaller than in control animals at every time point, including the final weight measurement (P < .02 at each comparison; Mann-Whitney U test). Horizontal lines in panel C indicate median values. Error bars indicate standard deviation from the mean. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

Gross appearance of LLC footpad tumors in mice with single and combined deficits in plasminogen and fibrinogen. Gross appearance of LLC footpad tumors in mice with single and combined deficits in plasminogen and fibrinogen. A normal, non-tumor–bearing foot (A) is shown along with examples of LLCGFP footpad tumors 14 days after inoculation into control (B), Plg– (C,F), Fib– (D), and Plg–/Fib– (E) mice. Despite the minimal difference in size between the Plg– tumor-bearing foot (C) and a non-tumor–bearing foot (A), the presence of tumor tissue could be easily appreciated using a fluorescence-equipped stereomicroscope (F). Note that the foot in panel F is the same foot shown in panel C and is photographed at the same magnification. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

LLC tumor growth is restored in the footpad of plasminogen-deficient mice by genetic elimination of fibrinogen. LLC tumor growth is restored in the footpad of plasminogen-deficient mice by genetic elimination of fibrinogen. (A) Weights of footpad tumors in cohorts of control •, Plg– ○, Fib– ▪, and Plg–/Fib– □ mice analyzed in parallel are shown 14 days after transplantation of LLCGFP. The weight distribution of footpad tumors was significantly smaller in Plg– mice than in control animals (P < .02), consistent with 2 other independent experiments. The elimination of fibrinogen relieved the impediment in tumor growth in Plg– mice. Indeed, footpad tumors from Plg–/Fib– mice were larger than those derived from control mice, though this difference was not statistically significant (P = .1). Plasminogen was not a significant determinant of tumor mass in the absence of fibrinogen (P = .7). Horizontal lines indicate median values. (B) Serial tumor width measurements demonstrated similar tumor expansion in fibrinogen-deficient mice with (▪, n = 7) and without (□, n = 7) plasminogen (P > .1 at each time point). All P values were established using the Mann-Whitney U test. Error bars indicate standard deviation from the mean. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

Histologic features of footpad tumors are similar in plasminogen-deficient and control mice. Histologic features of footpad tumors are similar in plasminogen-deficient and control mice. Shown are representative hematoxylin-eosin–stained sections of footpad LLCGFP tumors collected from control (A), Plg– (B), Fib– (C), and Plg–/Fib– (D) mice 14 days after initial transplantation. Note that the overall microscopic features of the tumor tissue were unremarkable within animals of each genotype and suggest no obvious basis for the impediment in tumor growth in Plg– mice. LLCGFP tumors grew as sheets of anaplastic cells that often invaded normal structures, including adjacent muscle and bone. Small areas of necrosis (*) were also present, but these were not appreciably different between animals of each genotype. Dermal surfaces of the footpads are indicated by arrows in panels A to D. Immunohistochemical staining for the endothelial marker PECAM (brown stain) revealed abundant vessels in footpad tumors derived from control (E) and plasminogen-deficient mice (F). Fibrin(ogen) immunostains revealed relatively scant and focal fibrin(ogen) deposition in control (G) and Plg– (H) mice (brown staining highlighted by arrows). Sparse fibrin(ogen) deposition was generally peritumoral or was associated with small areas of necrosis. Sections used for immunohistology were counterstained with hematoxylin. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

Occlusive microvascular thrombi are prominent in LLC footpad tumors derived from plasminogen-deficient mice. Occlusive microvascular thrombi are prominent in LLC footpad tumors derived from plasminogen-deficient mice. Electron microscopic evaluation of footpad tumor vasculature revealed widespread microvascular thrombi within tumors derived from Plg– mice (A-C) but not tumors collected from control (D), Fib– (E), or Plg–/Fib– (F) animals 14 days after initial tumor cell transplantation. These representative sections from Plg– mice include examples of vessels with small platelet aggregates (A) and vessels with advanced, highly occlusive thrombi (B-C). Occlusive platelet thrombi (arrowheads) were found in areas populated with viable tumor cells (*) and where the endothelium appeared essentially intact (arrows). Note that occlusive intravascular thrombi were not a feature of the rapidly growing tumors of control mice and Fib– mice. More significantly, no such platelet aggregates were observed in plasminogen-deficient mice lacking fibrinogen (F), animals that exhibited no impediment in tumor growth. Horizontal bars in each micrograph indicate 8 μm. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

Microvascular patency is maintained within LLC tumors of plasminogen-deficient mice when the tumors develop within the dorsal subcutis. Microvascular patency is maintained within LLC tumors of plasminogen-deficient mice when the tumors develop within the dorsal subcutis. Representative transmission electron micrographs illustrating dorsal skin tumor vasculatures of control (A), Plg– (B), Fib– (C), and Plg–/Fib– (D) mice. Note that in contrast to tumors grown in the footpad, tumors within the dorsal subcutis had no evidence of microvascular thrombus formation, regardless of animal genotype. Viable tumor cells are highlighted with asterisks, and endothelium is indicated with arrows. Horizontal bars in each micrograph indicate 8 μm. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology

Tumor cell mitotic index is diminished in footpad tumors derived from plasminogen-deficient mice relative to control animals. Tumor cell mitotic index is diminished in footpad tumors derived from plasminogen-deficient mice relative to control animals. Mitotic figures (arrowheads) were easily discernible in hematoxylin-eosin–stained sections of footpad tumors from control (A) and plasminogen-deficient (B) mice. (C) Quantitative analysis of mitotic indices within footpad tumors of mice with single and combined deficits in plasminogen and fibrinogen. The mitotic index observed in plasminogen-deficient (*) mice was significantly less than that observed in control animals (P < .02). In contrast, no significant difference in mitotic index was observed in comparative analyses of control animals and plasminogen-deficient mice that also lacked fibrinogen (P > .8). Mitotic indices were also similar in control and fibrinogen-deficient mice (P > .9). All P values were established using the Mann-Whitney U test. Error bars indicate standard deviation from the mean value for 6 mice. Joseph S. Palumbo et al. Blood 2003;102:2819-2827 ©2003 by American Society of Hematology